US5069911A
(en)
*
|
1985-02-05 |
1991-12-03 |
Sandoz Ltd. |
Pharmaceutical 9,10-dihydrogenated ergot alkaloid containing compositions
|
DE3636123A1
(de)
*
|
1986-10-23 |
1988-05-05 |
Rentschler Arzneimittel |
Arzneizubereitungen zur oralen verabreichung, die als einzeldosis 10 bis 240 mg dihydropyridin enthalten
|
FR2618073B1
(fr)
*
|
1987-07-16 |
1990-09-07 |
Pf Medicament |
Comprimes de type a matrice hydrophile a base de salbutamol et leur procede de preparation
|
US4994276A
(en)
*
|
1988-09-19 |
1991-02-19 |
Edward Mendell Co., Inc. |
Directly compressible sustained release excipient
|
DE3741149A1
(de)
*
|
1987-12-04 |
1989-06-15 |
Thomae Gmbh Dr K |
Zubereitungsformen zur verhinderung von adhaesionen von organen und organteilen
|
US5364622A
(en)
*
|
1987-12-04 |
1994-11-15 |
Dr. Karl Thomae Gmbh |
Methods for preventing adhesions to organs and parts of organs by application of tissue plasminogen activator and hydroxyethylcellulose hydrogel
|
US5023080A
(en)
*
|
1988-06-17 |
1991-06-11 |
Basic Bio Systems, Inc. |
Time release protein
|
US5055300A
(en)
*
|
1988-06-17 |
1991-10-08 |
Basic Bio Systems, Inc. |
Time release protein
|
US5079005A
(en)
*
|
1988-06-17 |
1992-01-07 |
Gupta Kashmiri L |
Time release protein
|
US5135757A
(en)
*
|
1988-09-19 |
1992-08-04 |
Edward Mendell Co., Inc. |
Compressible sustained release solid dosage forms
|
US5169639A
(en)
*
|
1988-09-19 |
1992-12-08 |
Edward Mendell Co., Inc. |
Controlled release verapamil tablets
|
HU203041B
(en)
*
|
1989-03-14 |
1991-05-28 |
Egyt Gyogyszervegyeszeti Gyar |
Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
|
US5275823A
(en)
*
|
1989-04-27 |
1994-01-04 |
Smith Kline & French Laboratories Ltd. |
Pharmaceutical compositions
|
DK0452262T3
(da)
*
|
1990-04-09 |
1996-02-05 |
Pfizer |
Presset tablet med reduceret kalorieindhold og forbedret fornemmelse i munden
|
US5403593A
(en)
*
|
1991-03-04 |
1995-04-04 |
Sandoz Ltd. |
Melt granulated compositions for preparing sustained release dosage forms
|
US5221698A
(en)
*
|
1991-06-27 |
1993-06-22 |
The Regents Of The University Of Michigan |
Bioactive composition
|
US5225201A
(en)
*
|
1991-08-23 |
1993-07-06 |
Minnesota Mining And Manufacturing Company |
Salsalate tablet
|
FI93924C
(fi)
*
|
1991-09-17 |
1995-06-26 |
Martti Lauri Antero Marvola |
Menetelmä säädellysti lääkeainetta vapauttavan valmisteen valmistamiseksi
|
CA2082185C
(fr)
*
|
1991-11-26 |
2004-01-20 |
Alexander R. Pokora |
Traitement catalytique de matieres lignocellulosiques a l'aide de protease
|
US5266331A
(en)
*
|
1991-11-27 |
1993-11-30 |
Euroceltique, S.A. |
Controlled release oxycodone compositions
|
US5958459A
(en)
*
|
1991-12-24 |
1999-09-28 |
Purdue Pharma L.P. |
Opioid formulations having extended controlled released
|
US5968551A
(en)
*
|
1991-12-24 |
1999-10-19 |
Purdue Pharma L.P. |
Orally administrable opioid formulations having extended duration of effect
|
US5478577A
(en)
*
|
1993-11-23 |
1995-12-26 |
Euroceltique, S.A. |
Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
|
GB9200607D0
(en)
*
|
1992-01-13 |
1992-03-11 |
Ethical Pharma Ltd |
Pharmaceutical compositions containing nifedipine and process for the preparation thereof
|
US5472711A
(en)
*
|
1992-07-30 |
1995-12-05 |
Edward Mendell Co., Inc. |
Agglomerated hydrophilic complexes with multi-phasic release characteristics
|
US20080075781A1
(en)
*
|
1992-11-25 |
2008-03-27 |
Purdue Pharma Lp |
Controlled release oxycodone compositions
|
USRE39300E1
(en)
|
1993-01-28 |
2006-09-19 |
Virginia Commonwealth University Medical College Of Virginia |
Inhibiting the development of tolerance to and/or dependence on an addictive substance
|
US5321012A
(en)
*
|
1993-01-28 |
1994-06-14 |
Virginia Commonwealth University Medical College |
Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
|
NZ260408A
(en)
*
|
1993-05-10 |
1996-05-28 |
Euro Celtique Sa |
Controlled release preparation comprising tramadol
|
US20070275062A1
(en)
*
|
1993-06-18 |
2007-11-29 |
Benjamin Oshlack |
Controlled release oxycodone compositions
|
IL110014A
(en)
*
|
1993-07-01 |
1999-11-30 |
Euro Celtique Sa |
Solid controlled-release oral dosage forms of opioid analgesics
|
US7740881B1
(en)
|
1993-07-01 |
2010-06-22 |
Purdue Pharma Lp |
Method of treating humans with opioid formulations having extended controlled release
|
US5879705A
(en)
*
|
1993-07-27 |
1999-03-09 |
Euro-Celtique S.A. |
Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
|
US6129930A
(en)
|
1993-09-20 |
2000-10-10 |
Bova; David J. |
Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
|
US6818229B1
(en)
|
1993-09-20 |
2004-11-16 |
Kos Pharmaceuticals, Inc. |
Intermediate release nicotinic acid compositions for treating hyperlipidemia
|
US6746691B2
(en)
|
1993-09-20 |
2004-06-08 |
Kos Pharmaceuticals, Inc. |
Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
|
US6080428A
(en)
|
1993-09-20 |
2000-06-27 |
Bova; David J. |
Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
|
US20060263428A1
(en)
*
|
1993-09-20 |
2006-11-23 |
Eugenio Cefali |
Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
|
US6676967B1
(en)
*
|
1993-09-20 |
2004-01-13 |
Kos Pharmaceuticals, Inc. |
Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
|
KR100354702B1
(ko)
*
|
1993-11-23 |
2002-12-28 |
유로-셀티크 소시에떼 아노뉨 |
약학조성물의제조방법및서방형조성물
|
US5891471A
(en)
*
|
1993-11-23 |
1999-04-06 |
Euro-Celtique, S.A. |
Pharmaceutical multiparticulates
|
US5843480A
(en)
*
|
1994-03-14 |
1998-12-01 |
Euro-Celtique, S.A. |
Controlled release diamorphine formulation
|
GB9422154D0
(en)
|
1994-11-03 |
1994-12-21 |
Euro Celtique Sa |
Pharmaceutical compositions and method of producing the same
|
US5965161A
(en)
|
1994-11-04 |
1999-10-12 |
Euro-Celtique, S.A. |
Extruded multi-particulates
|
US20020006438A1
(en)
*
|
1998-09-25 |
2002-01-17 |
Benjamin Oshlack |
Sustained release hydromorphone formulations exhibiting bimodal characteristics
|
US5744164A
(en)
*
|
1994-12-16 |
1998-04-28 |
Nestec S.A. |
Sustained release microparticulate caffeine formulation
|
EP0742008A1
(fr)
*
|
1995-05-11 |
1996-11-13 |
Euro-Celtique S.A. |
Compositions pharmaceutiques à libération contrÔlée
|
US5931809A
(en)
|
1995-07-14 |
1999-08-03 |
Depotech Corporation |
Epidural administration of therapeutic compounds with sustained rate of release
|
GB9519363D0
(en)
|
1995-09-22 |
1995-11-22 |
Euro Celtique Sa |
Pharmaceutical formulation
|
IT1276130B1
(it)
|
1995-11-14 |
1997-10-27 |
Gentili Ist Spa |
Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
|
US20060062843A1
(en)
*
|
1996-03-25 |
2006-03-23 |
Wyeth |
Extended release formulation
|
SE9704401D0
(sv)
*
|
1997-11-28 |
1997-11-28 |
Astra Ab |
Matrix pellets for greasy, oily or sticky drug substances
|
HUP0100310A3
(en)
*
|
1997-12-22 |
2002-11-28 |
Euro Celtique Sa |
A method of preventing abuse of opioid dosage forms
|
CA2314893C
(fr)
|
1997-12-22 |
2005-09-13 |
Euro-Celtique, S.A. |
Combinaison d'agonistes et d'antagonistes d'opioides
|
CN1203846C
(zh)
|
1998-03-19 |
2005-06-01 |
布里斯托尔-迈尔斯斯奎布公司 |
高溶解性药物的双相控释递送系统和方法
|
US6099859A
(en)
*
|
1998-03-20 |
2000-08-08 |
Andrx Pharmaceuticals, Inc. |
Controlled release oral tablet having a unitary core
|
US6806294B2
(en)
|
1998-10-15 |
2004-10-19 |
Euro-Celtique S.A. |
Opioid analgesic
|
UA74141C2
(uk)
*
|
1998-12-09 |
2005-11-15 |
Дж.Д. Сірл Енд Ко. |
Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
|
US6419960B1
(en)
|
1998-12-17 |
2002-07-16 |
Euro-Celtique S.A. |
Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
|
US6673367B1
(en)
*
|
1998-12-17 |
2004-01-06 |
Euro-Celtique, S.A. |
Controlled/modified release oral methylphenidate formulations
|
DE19918325A1
(de)
|
1999-04-22 |
2000-10-26 |
Euro Celtique Sa |
Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
|
US6555139B2
(en)
|
1999-06-28 |
2003-04-29 |
Wockhardt Europe Limited |
Preparation of micron-size pharmaceutical particles by microfluidization
|
US6878749B2
(en)
*
|
1999-09-17 |
2005-04-12 |
Novartis Ag |
Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
|
US7537785B2
(en)
*
|
1999-10-29 |
2009-05-26 |
Nitromed, Inc. |
Composition for treating vascular diseases characterized by nitric oxide insufficiency
|
MXPA02004293A
(es)
|
1999-10-29 |
2002-10-31 |
Euro Celtique Sa |
Formulaciones de hidrocodona de liberacion controlada..
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
AU780261B2
(en)
|
1999-10-29 |
2005-03-10 |
Nitromed, Inc. |
Methods of treating vascular diseases characterized by nitric oxide insufficiency
|
US7771746B2
(en)
*
|
1999-12-03 |
2010-08-10 |
Polichem Sa |
Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof
|
EP1299104B1
(fr)
|
2000-02-08 |
2009-05-13 |
Euro-Celtique S.A. |
Formes orales inviolables a base d'agonistes opioides
|
US6544555B2
(en)
|
2000-02-24 |
2003-04-08 |
Advancis Pharmaceutical Corp. |
Antibiotic product, use and formulation thereof
|
US6565882B2
(en)
|
2000-02-24 |
2003-05-20 |
Advancis Pharmaceutical Corp |
Antibiotic composition with inhibitor
|
US6855721B1
(en)
|
2000-07-28 |
2005-02-15 |
Indevus Pharmaceuticals, Inc. |
Methods and compositions for alleviating stuttering
|
SE0003125D0
(sv)
*
|
2000-09-05 |
2000-09-05 |
Astrazeneca Ab |
Modified polymers
|
US6541014B2
(en)
|
2000-10-13 |
2003-04-01 |
Advancis Pharmaceutical Corp. |
Antiviral product, use and formulation thereof
|
US20020068078A1
(en)
|
2000-10-13 |
2002-06-06 |
Rudnic Edward M. |
Antifungal product, use and formulation thereof
|
EP1337244A4
(fr)
|
2000-10-30 |
2006-01-11 |
Euro Celtique Sa |
Preparations d'hydrocodone a liberation lente
|
US20020197314A1
(en)
*
|
2001-02-23 |
2002-12-26 |
Rudnic Edward M. |
Anti-fungal composition
|
UA81224C2
(uk)
*
|
2001-05-02 |
2007-12-25 |
Euro Celtic S A |
Дозована форма оксикодону та її застосування
|
US20110104214A1
(en)
|
2004-04-15 |
2011-05-05 |
Purdue Pharma L.P. |
Once-a-day oxycodone formulations
|
DE60238756D1
(de)
|
2001-05-11 |
2011-02-10 |
Endo Pharmaceuticals Inc |
Opioid enthaltende arzneiform gegen missbrauch
|
CA2454328C
(fr)
*
|
2001-07-18 |
2008-03-18 |
Christopher D. Breder |
Combinaisons pharmaceutiques d'oxycodone et naloxone
|
US7504395B2
(en)
*
|
2001-07-20 |
2009-03-17 |
Psychogenics, Inc. |
Treatment for attention-deficit hyperactivity disorder
|
US20030044458A1
(en)
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
WO2003013433A2
(fr)
|
2001-08-06 |
2003-02-20 |
Euro-Celtique S.A. |
Formulations d'antagoniste sequestre
|
CA2457361C
(fr)
|
2001-08-06 |
2008-11-04 |
Christopher Breder |
Formulations d'agoniste opioide a antagoniste liberable et sequestre
|
US10285910B2
(en)
|
2001-10-12 |
2019-05-14 |
Aquestive Therapeutics, Inc. |
Sublingual and buccal film compositions
|
US8765167B2
(en)
|
2001-10-12 |
2014-07-01 |
Monosol Rx, Llc |
Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
|
US11207805B2
(en)
|
2001-10-12 |
2021-12-28 |
Aquestive Therapeutics, Inc. |
Process for manufacturing a resulting pharmaceutical film
|
US20110033542A1
(en)
|
2009-08-07 |
2011-02-10 |
Monosol Rx, Llc |
Sublingual and buccal film compositions
|
US20190328679A1
(en)
|
2001-10-12 |
2019-10-31 |
Aquestive Therapeutics, Inc. |
Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
|
US7357891B2
(en)
|
2001-10-12 |
2008-04-15 |
Monosol Rx, Llc |
Process for making an ingestible film
|
US8900497B2
(en)
|
2001-10-12 |
2014-12-02 |
Monosol Rx, Llc |
Process for making a film having a substantially uniform distribution of components
|
US8900498B2
(en)
|
2001-10-12 |
2014-12-02 |
Monosol Rx, Llc |
Process for manufacturing a resulting multi-layer pharmaceutical film
|
US8603514B2
(en)
|
2002-04-11 |
2013-12-10 |
Monosol Rx, Llc |
Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
|
US20070281003A1
(en)
|
2001-10-12 |
2007-12-06 |
Fuisz Richard C |
Polymer-Based Films and Drug Delivery Systems Made Therefrom
|
US7612112B2
(en)
|
2001-10-25 |
2009-11-03 |
Depomed, Inc. |
Methods of treatment using a gastric retained gabapentin dosage
|
TWI312285B
(en)
|
2001-10-25 |
2009-07-21 |
Depomed Inc |
Methods of treatment using a gastric retained gabapentin dosage
|
US20060159743A1
(en)
*
|
2001-10-25 |
2006-07-20 |
Depomed, Inc. |
Methods of treating non-nociceptive pain states with gastric retentive gabapentin
|
EP2425821B1
(fr)
|
2002-04-05 |
2017-05-10 |
Euro-Celtique S.A. |
Préparation pharmaceutique contenant de l'oxycodone et de la naloxone
|
AU2003301808A1
(en)
*
|
2002-05-13 |
2004-06-07 |
Endo Pharmaceuticals Inc. |
Abuse-resistant opioid dosage form
|
US20060073102A1
(en)
*
|
2002-05-13 |
2006-04-06 |
Huaihung Kao D |
Abuse-resistant opioid solid dosage form
|
KR100897890B1
(ko)
|
2002-06-17 |
2009-05-18 |
인벤티아 헬스케어 피브이티. 엘티디. |
티아졸리딘디온 및 바이구아나이드를 함유하는 다층 정제및 그의 제조 방법
|
CA2494281A1
(fr)
*
|
2002-08-02 |
2004-02-12 |
Penwest Pharmaceuticals Company |
Preparations a liberation soutenue de metformine
|
EP2422773A3
(fr)
*
|
2002-09-20 |
2012-04-18 |
Alpharma, Inc. |
Séquestration de sous-unité et compositions et procédés associés
|
US20040086566A1
(en)
*
|
2002-11-04 |
2004-05-06 |
Alpharma, Inc. |
Waxy matrix dosage forms
|
US20040202717A1
(en)
|
2003-04-08 |
2004-10-14 |
Mehta Atul M. |
Abuse-resistant oral dosage forms and method of use thereof
|
MY135852A
(en)
*
|
2003-04-21 |
2008-07-31 |
Euro Celtique Sa |
Pharmaceutical products
|
US20050042289A1
(en)
*
|
2003-04-29 |
2005-02-24 |
Yamanouchi Pharma Technologies, Inc. |
Tablets and methods for modified release of hydrophylic and other active agents
|
ES2303085T3
(es)
|
2003-04-29 |
2008-08-01 |
Orexigen Therapeutics, Inc. |
Composiciones que afectan a la perdida de peso.
|
BR0302017B1
(pt)
|
2003-06-02 |
2014-10-29 |
Ems Sigma Pharma Ltda |
Composição farmacêutica sublingual a base de um agonista do receptor central de benzodiazepínicos
|
WO2005009365A2
(fr)
|
2003-07-21 |
2005-02-03 |
Advancis Pharmaceutical Corporation |
Produit antibiotique, son utilisation et sa formulation
|
JP2006528185A
(ja)
|
2003-07-21 |
2006-12-14 |
アドバンシス ファーマスーティカル コーポレイション |
抗生物質製剤、その使用法及び作成方法
|
WO2005009368A2
(fr)
|
2003-07-21 |
2005-02-03 |
Advancis Pharmaceutical Corporation |
Produit antibiotique, utilisation et formulation correspondantes
|
US8758820B2
(en)
|
2003-08-11 |
2014-06-24 |
Shionogi Inc. |
Robust pellet
|
CA2535398C
(fr)
|
2003-08-12 |
2013-11-12 |
Advancis Pharmaceuticals Corporation |
Antibiotique, utilisation et formulation associees
|
AU2004270170B2
(en)
|
2003-08-29 |
2011-01-27 |
Shionogi, Inc. |
Antibiotic product, use and formulation thereof
|
CA2538064C
(fr)
|
2003-09-15 |
2013-12-17 |
Advancis Pharmaceutical Corporation |
Antibiotique, son utilisation et sa formulation
|
JP5610663B2
(ja)
*
|
2003-11-04 |
2014-10-22 |
スパーナス ファーマシューティカルズ インコーポレイテッド |
トロスピウムの1日1回剤形
|
US8709476B2
(en)
|
2003-11-04 |
2014-04-29 |
Supernus Pharmaceuticals, Inc. |
Compositions of quaternary ammonium compounds containing bioavailability enhancers
|
US20050202079A1
(en)
*
|
2004-03-15 |
2005-09-15 |
Mylan Pharmaceuticals Inc. |
Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation
|
MXPA06012564A
(es)
|
2004-04-27 |
2007-01-31 |
Medicinova Inc |
Derivados de acido fenoxialquilcarboxilico en el tratamiento de enfermedades inflamatorias.
|
CA2576232C
(fr)
*
|
2004-05-14 |
2009-10-27 |
Green Cross Corp. |
Proprietes neuroprotectrices de morphinanes de dextrorotation
|
EP1604666A1
(fr)
*
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioides pour le traitement de la bronchopneumopathie chronique obstructive
|
AU2005269981A1
(en)
|
2004-07-02 |
2006-02-09 |
Bonck, John A |
Tablet for pulsed delivery
|
FR2875409B1
(fr)
*
|
2004-09-17 |
2010-05-07 |
Sanofi Aventis |
Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
|
WO2006058236A2
(fr)
|
2004-11-24 |
2006-06-01 |
Neuromolecular Pharmaceuticals, Inc. |
Composition et methode pour traiter des affections neurologiques
|
EP1702558A1
(fr)
*
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Procédé et dispositif pour évaluer la fonction de l'activité intestinale
|
WO2007002597A2
(fr)
|
2005-06-27 |
2007-01-04 |
Biovail Laboratories International S.R.L. |
Formulations a liberation modifiee d'un sel de bupropion
|
JP2009514884A
(ja)
*
|
2005-11-04 |
2009-04-09 |
イーストマン ケミカル カンパニー |
難溶性医薬活性剤の投与のためのカルボキシアルキルセルロースエステル
|
BRPI0618918B8
(pt)
|
2005-11-22 |
2021-05-25 |
Nalpropion Pharmaceuticals Llc |
uso de um primeiro composto e um segundo composto para tratar uma condição de glicose sanguínea
|
US8357394B2
(en)
|
2005-12-08 |
2013-01-22 |
Shionogi Inc. |
Compositions and methods for improved efficacy of penicillin-type antibiotics
|
US8778924B2
(en)
|
2006-12-04 |
2014-07-15 |
Shionogi Inc. |
Modified release amoxicillin products
|
US20090176882A1
(en)
*
|
2008-12-09 |
2009-07-09 |
Depomed, Inc. |
Gastric retentive gabapentin dosage forms and methods for using same
|
US8299052B2
(en)
*
|
2006-05-05 |
2012-10-30 |
Shionogi Inc. |
Pharmaceutical compositions and methods for improved bacterial eradication
|
US8916195B2
(en)
|
2006-06-05 |
2014-12-23 |
Orexigen Therapeutics, Inc. |
Sustained release formulation of naltrexone
|
US20070281017A1
(en)
*
|
2006-06-06 |
2007-12-06 |
Endo Pharmaceuticals Inc., A Delaware Corporation |
Sustained release oxycodone composition with acrylic polymer and metal hydroxide
|
KR20140079441A
(ko)
|
2006-06-19 |
2014-06-26 |
알파마 파머슈티컬스 엘엘씨 |
약제학적 조성물
|
AU2007275034A1
(en)
*
|
2006-07-21 |
2008-01-24 |
Lab International Srl |
Hydrophilic abuse deterrent delivery system
|
MX343867B
(es)
|
2006-11-09 |
2016-11-25 |
Orexigen Therapeutics Inc |
Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
US20100151014A1
(en)
*
|
2008-12-16 |
2010-06-17 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
US20090246276A1
(en)
|
2008-01-28 |
2009-10-01 |
Graham Jackson |
Pharmaceutical Compositions
|
MX2010012909A
(es)
|
2008-05-30 |
2011-02-25 |
Orexigen Therapeutics Inc |
Metodos para tratamiento de condiciones de grasa visceral.
|
WO2010003963A1
(fr)
*
|
2008-07-07 |
2010-01-14 |
Euro-Celtique S.A. |
Utilisation d'antagonistes opioïdes pour le traitement d'une rétention urinaire
|
CN102186886B
(zh)
|
2008-08-20 |
2015-08-19 |
卡吉尔公司 |
新型聚葡萄糖材料
|
JP5886632B2
(ja)
|
2009-03-10 |
2016-03-16 |
ユーロ−セルティーク エス.エイ. |
オキシコドンおよびナロキソンを含む即時放出医薬組成物
|
US10525152B2
(en)
|
2009-10-09 |
2020-01-07 |
Signablok, Inc. |
Methods and compositions for targeted imaging
|
AU2010325960C1
(en)
|
2009-12-02 |
2015-08-06 |
Adamas Pharma, Llc |
Amantadine compositions and methods of use
|
AU2011203867B2
(en)
|
2010-01-11 |
2015-12-03 |
Nalpropion Pharmaceuticals Llc |
Methods of providing weight loss therapy in patients with major depression
|
US9149959B2
(en)
|
2010-10-22 |
2015-10-06 |
Monosol Rx, Llc |
Manufacturing of small film strips
|
US8962687B2
(en)
|
2012-12-05 |
2015-02-24 |
Medicinova, Inc. |
Method of treating liver disorders
|
US8835499B2
(en)
|
2011-12-08 |
2014-09-16 |
Medicinova, Inc. |
Method of treating non-alcoholic fatty liver disease and steatohepatitis
|
US9480745B2
(en)
|
2012-02-29 |
2016-11-01 |
University Hospitals Cleveland Medical Center |
Targeted treatment of anerobic cancer
|
EP2858640B1
(fr)
|
2012-06-06 |
2020-03-25 |
Nalpropion Pharmaceuticals LLC |
Composition à être utilisée dans une méthode de traitement de la surcharge pondérale et de l'obésité dans de patients présentant un risque cardiovasculaire élevé
|
US20150133664A1
(en)
|
2012-06-07 |
2015-05-14 |
Board Of Regents, The University Of Texas System |
Chemical transformations of (-)-codeine to afford derivatives of codeine and morphine thereof
|
CA2881726A1
(fr)
*
|
2012-08-23 |
2014-02-27 |
Cardiolynx Ag |
Compositions de nitrate d'aminoalkyle a diffusion prolongee
|
US10154971B2
(en)
|
2013-06-17 |
2018-12-18 |
Adamas Pharma, Llc |
Methods of administering amantadine
|
KR20160034352A
(ko)
|
2013-07-23 |
2016-03-29 |
유로-셀티큐 에스.에이. |
장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물
|
WO2015013395A1
(fr)
|
2013-07-25 |
2015-01-29 |
Medicinova, Inc. |
Procédés pour réduire les niveaux de sang de triglycéride, de cholestérol total et de lipoprotéine de basse densité
|
EP3068880A4
(fr)
|
2013-11-11 |
2017-06-14 |
University Hospitals Cleveland Medical Center |
Traitement ciblé de cancer anaérobie
|
US8969371B1
(en)
|
2013-12-06 |
2015-03-03 |
Orexigen Therapeutics, Inc. |
Compositions and methods for weight loss in at risk patient populations
|
US20150321989A1
(en)
|
2014-05-08 |
2015-11-12 |
Medicinova, Inc. |
Method of treating idiopathic pulmonary fibrosis
|
US9346754B2
(en)
|
2014-05-08 |
2016-05-24 |
Medicinova, Inc. |
Method of treating advanced non-alcoholic steatohepatitis
|
CA2950909C
(fr)
|
2014-06-02 |
2023-03-28 |
Medicinova, Inc. |
Procede d'inhibition ou de traitement de la fibrose
|
CA2936748C
(fr)
|
2014-10-31 |
2017-08-08 |
Purdue Pharma |
Methodes et compositions destinees au traitement du trouble de deficit d'attention
|
US10258611B2
(en)
|
2014-11-26 |
2019-04-16 |
Medicinova, Inc. |
Combination of ibudilast and riluzole and methods of using same
|
US9861629B1
(en)
|
2015-10-07 |
2018-01-09 |
Banner Life Sciences Llc |
Opioid abuse deterrent dosage forms
|
US10335405B1
(en)
|
2016-05-04 |
2019-07-02 |
Patheon Softgels, Inc. |
Non-burst releasing pharmaceutical composition
|
KR20190005199A
(ko)
|
2016-05-05 |
2019-01-15 |
어퀘스티브 테라퓨틱스, 아이엔씨. |
강화된 전달 에프네프린 조성물
|
US11273131B2
(en)
|
2016-05-05 |
2022-03-15 |
Aquestive Therapeutics, Inc. |
Pharmaceutical compositions with enhanced permeation
|
US10335375B2
(en)
|
2017-05-30 |
2019-07-02 |
Patheon Softgels, Inc. |
Anti-overingestion abuse deterrent compositions
|
AU2018360383A1
(en)
|
2017-11-02 |
2020-05-21 |
Natureceuticals Sdn. Bhd. |
Extract of orthosiphon stamineus, formulations, and uses thereof
|
US10722473B2
(en)
|
2018-11-19 |
2020-07-28 |
Purdue Pharma L.P. |
Methods and compositions particularly for treatment of attention deficit disorder
|
CN117320701A
(zh)
|
2021-05-28 |
2023-12-29 |
美迪诺亚公司 |
一种降低肝脏中甘油三酯合成的方法
|